Skip to main content
Premium Trial:

Request an Annual Quote

BCCA's Genome Sciences Centre Joins Illumina Genome Network


The British Columbia Cancer Agency's Michael Smith Genome Sciences Centre has joined the Illumina Genome Network as a provider of human whole-genome sequencing services, Illumina said this week.

Through the IGN, the company offers human genome sequencing services to researchers, as of this summer priced at $5,000 per genome for projects of at least 10 samples, and $4,000 per genome for projects of at least 50 samples.

Existing members of the IGN are the University of Washington Department of Genome Sciences, the National Center for Genome Resources in New Mexico, the Macrogen/Genomic Medicine Institute in Korea, and Illumina's own FastTrack services lab.

Illumina had already announced GSC's membership during its third-quarter earnings call in October (IS 10/25/2011).

All IGN partners have been certified by Illumina as service providers and possess at least 10 HiSeq 2000 or Genome Analyzer sequencers.

According to its website, the GSC currently has 12 HiSeq 2000 systems. But the center also installed a large number of SOLiD systems from Illumina's rival, Life Technologies, purchasing a total of 10 SOLiDs for whole-genome sequencing of cancer samples last year (IS 4/13/2010).

Marco Marra, the center's director, was not available before deadline for an update on the GSC's sequencing equipment.

The Scan

Shape of Them All

According to BBC News, researchers have developed a protein structure database that includes much of the human proteome.

For Flu and More

The Wall Street Journal reports that several vaccine developers are working on mRNA-based vaccines for influenza.

To Boost Women

China's Ministry of Science and Technology aims to boost the number of female researchers through a new policy, reports the South China Morning Post.

Science Papers Describe Approach to Predict Chemotherapeutic Response, Role of Transcriptional Noise

In Science this week: neural network to predict chemotherapeutic response in cancer patients, and more.